Literature DB >> 16496032

Brain imaging and cognitive dysfunctions in Huntington's disease.

Alonso Montoya1, Bruce H Price, Matthew Menear, Martin Lepage.   

Abstract

Recent decades have seen tremendous growth in our understanding of the cognitive dysfunctions observed in Huntington's disease (HD). Advances in neuroimaging have contributed greatly to this growth. We reviewed the role that structural and functional neuroimaging techniques have played in elucidating the cerebral bases of the cognitive deficits associated with HD. We conducted a computer-based search using PubMed and PsycINFO databases to retrieve studies of patients with HD published between 1965 and December 2004 that reported measures on cognitive tasks and used neuroimaging techniques. Structural neuroimaging has provided important evidence of morphological brain changes in HD. Striatal and cortical atrophy are the most common findings, and they correlate with cognitive deficits in attention, working memory and executive functions. Functional studies have also demonstrated correlations between striatal dysfunction and cognitive performance. Striatal hypoperfusion and decreased glucose utilization correlate with executive dysfunction. Hypometabolism also occurs throughout the cerebral cortex and correlates with performance on recognition memory, language and perceptual tests. Measures of presynaptic and postsynaptic dopamine biochemistry have also correlated with measurements of episodic memory, speed of processing and executive functioning. Aided by the results of numerous neuroimaging studies, it is becoming increasingly clear that cognitive deficits in HD involve abnormal connectivity between the basal ganglia and cortical areas. In the future, neuroimaging techniques may shed the most light on the pathophysiology of HD by defining neurodegenerative disease phenotypes as a valuable tool for knowing when patients become "symptomatic," having been in a gene-positive presymptomatic state, and as a biomarker in following the disease, thereby providing a prospect for improved patient care.

Entities:  

Mesh:

Year:  2006        PMID: 16496032      PMCID: PMC1325063     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  65 in total

Review 1.  Neurovascular regulation in the normal brain and in Alzheimer's disease.

Authors:  Costantino Iadecola
Journal:  Nat Rev Neurosci       Date:  2004-05       Impact factor: 34.870

2.  Prefrontal cortical blood flow and cognitive function in Huntington's disease.

Authors:  D R Weinberger; K F Berman; M Iadarola; N Driesen; R F Zec
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-01       Impact factor: 10.154

3.  Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.

Authors:  B Kremer; C M Clark; E W Almqvist; L A Raymond; P Graf; C Jacova; M Mezei; M A Hardy; B Snow; W Martin; M R Hayden
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

4.  Altered functional MRI responses in Huntington's disease.

Authors:  Vincent P Clark; Song Lai; A Wallace Deckel
Journal:  Neuroreport       Date:  2002-04-16       Impact factor: 1.837

5.  Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.

Authors:  G J Harris; G D Pearlson; C E Peyser; E H Aylward; J Roberts; P E Barta; G A Chase; S E Folstein
Journal:  Ann Neurol       Date:  1992-01       Impact factor: 10.422

6.  Reduced regional cerebral blood flow in Huntington's disease studied by SPECT.

Authors:  S G Hasselbalch; G Oberg; S A Sørensen; A R Andersen; G Waldemar; J F Schmidt; K Fenger; O B Paulson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

7.  Cerebral structure on MRI, Part II: Specific changes in Alzheimer's and Huntington's diseases.

Authors:  T L Jernigan; D P Salmon; N Butters; J R Hesselink
Journal:  Biol Psychiatry       Date:  1991-01-01       Impact factor: 13.382

8.  Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study.

Authors:  K A Bamford; E D Caine; D K Kido; W M Plassche; I Shoulson
Journal:  Neurology       Date:  1989-06       Impact factor: 9.910

9.  Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function.

Authors:  S Berent; B Giordani; S Lehtinen; D Markel; J B Penney; H A Buchtel; S Starosta-Rubinstein; R Hichwa; A B Young
Journal:  Ann Neurol       Date:  1988-06       Impact factor: 10.422

10.  PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.

Authors:  A B Young; J B Penney; S Starosta-Rubinstein; D S Markel; S Berent; B Giordani; R Ehrenkaufer; D Jewett; R Hichwa
Journal:  Ann Neurol       Date:  1986-09       Impact factor: 10.422

View more
  61 in total

1.  Reduced expression of conditioned fear in the R6/2 mouse model of Huntington's disease is related to abnormal activity in prelimbic cortex.

Authors:  Adam G Walker; Jason R Ummel; George V Rebec
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

Review 2.  Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission.

Authors:  P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2014-03-28       Impact factor: 7.851

Review 3.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

4.  Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease.

Authors:  Rajat Sandhir; Aarti Yadav; Arpit Mehrotra; Aditya Sunkaria; Amandeep Singh; Sadhna Sharma
Journal:  Neuromolecular Med       Date:  2013-09-06       Impact factor: 3.843

5.  The BACHD Rat Model of Huntington Disease Shows Signs of Fronto-Striatal Dysfunction in Two Operant Conditioning Tests of Short-Term Memory.

Authors:  Erik Karl Håkan Clemensson; Laura Emily Clemensson; Olaf Riess; Huu Phuc Nguyen
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

Review 6.  Neuroimaging of rapidly progressive dementias, part 1: neurodegenerative etiologies.

Authors:  A J Degnan; L M Levy
Journal:  AJNR Am J Neuroradiol       Date:  2013-02-22       Impact factor: 3.825

7.  Dynamin-related protein 1 heterozygote knockout mice do not have synaptic and mitochondrial deficiencies.

Authors:  Maria Manczak; Hiromi Sesaki; Yusuke Kageyama; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2012-02-23

Review 8.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

9.  Cognitive reserve and brain reserve in prodromal Huntington's disease.

Authors:  Aaron Bonner-Jackson; Jeffrey D Long; Holly Westervelt; Geoffrey Tremont; Elizabeth Aylward; Jane S Paulsen
Journal:  J Int Neuropsychol Soc       Date:  2013-05-23       Impact factor: 2.892

Review 10.  Magnetic resonance imaging of Huntington's disease: preparing for clinical trials.

Authors:  S Klöppel; S M Henley; N Z Hobbs; R C Wolf; J Kassubek; S J Tabrizi; R S J Frackowiak
Journal:  Neuroscience       Date:  2009-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.